Along with its heterogeneity is its poor response to drug treatments which could be in part due to underlying molecular changes altering its genetic stability [38, 39] One such study identified, BRAF inhibition by the small-molecule drug PLX4032 is extremely effective in melanoma treatment but colon cancer cells with the same BRAF lesions do not respond to the same drug [39]. The gene discussed is BRAF; the disease is colonic neoplasm.